Randal Chase
Director/Board Member at GEOVAX LABS, INC.
Net worth: 3 588 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Robert McNally | M | 76 | 18 years | |
| David Dodd | M | 74 | 14 years | |
| Paul Woodward | M | 63 | 6 years | |
| Mark Reynolds | M | 62 | 18 years | |
| John Spencer | M | 83 | 18 years | |
| Dean Kollintzas | M | 50 | 18 years | |
| Nicole Lemerond | F | 48 | 2 years | |
| Mark Newman | M | 69 | 4 years | |
| Michael Watson | M | - |
Acambis Plc
 Acambis Plc BiotechnologyHealth Technology Acambis Plc develops biopharmaceutical products and vaccines. It offers ACAM2000, a smallpox vaccine for emergency-use stockpiling; and ChimeriVax-JE, a single-dose Japanese encephalitis vaccine for endemic markets and travelers. Its products in pipeline include ChimeriVax-JE, ChimeriVax-West Nile, and ChimeriVax-Dengue. The company was founded in 1992 and is headquartered in Cambridge, UK. | 17 years |
| Kelly McKee | M | 74 | 2 years | |
| John Sharkey | M | 67 | 2 years | |
| Erica Raiden | F | - | 2 years | |
| Jayne Morgan | M | 61 | 2 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| William A. Cochrane | M | 98 |
Rhino Resources, Inc. (Canada)
Immunovaccine Technologies, Inc.
| 10 years |
| Gary Dodge | M | - |
Immunovaccine Technologies, Inc.
| - |
| Paul Kirkconnell | M | - | 3 years | |
| Brian E. Lowe | M | 71 |
Immunovaccine Technologies, Inc.
| 3 years |
| Andrew Sheldon | M | - |
Medicago, Inc.
 Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | - |
| Michael Kirby | M | 81 |
Immunovaccine Technologies, Inc.
| - |
| Ossama R. Hassanein | M | - |
University of British Columbia
| 4 years |
| Albert Scardino | M | 76 | 10 years | |
| Jerald S. Cobbs | M | 71 | - | |
| David Tierney | M | 60 | - | |
| Denis Ryan | M | 81 |
Rhino Resources, Inc. (Canada)
Immunovaccine Technologies, Inc.
| - |
| Pierre Seccareccia | M | 77 |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | - |
| David de Witt | M | 71 |
University of British Columbia
| 7 years |
| John William Greenslade | M | 75 |
University of British Columbia
| 6 years |
| Keith Abriel | M | 51 |
Rhino Resources, Inc. (Canada)
| - |
| Michael Edward O'Connor | M | - |
University of British Columbia
| 4 years |
| Gary W. Hayes | M | - | 11 years | |
| Edward L. Flynn | M | 89 | - | |
| Douglas Eacrett | M | 78 |
University of British Columbia
| 6 years |
| David Lawrence | M | 61 |
Acambis Plc
Acambis Plc BiotechnologyHealth Technology Acambis Plc develops biopharmaceutical products and vaccines. It offers ACAM2000, a smallpox vaccine for emergency-use stockpiling; and ChimeriVax-JE, a single-dose Japanese encephalitis vaccine for endemic markets and travelers. Its products in pipeline include ChimeriVax-JE, ChimeriVax-West Nile, and ChimeriVax-Dengue. The company was founded in 1992 and is headquartered in Cambridge, UK. | 3 years |
| Ralph Makar | M | 63 | 4 years | |
| Thom Skinner | M | - | 1 years | |
| Glenn Yeadon | M | 73 |
University of British Columbia
| 5 years |
| Bradley Thompson | M | 67 | - | |
| Daniel Abdun-Nabi | M | 69 |
North American Vaccine, Inc.
 North American Vaccine, Inc. Pharmaceuticals: OtherHealth Technology North American Vaccine, Inc. develops and sells vaccines for the prevention of infectious diseases. The company is based in Columbia, MD. The company was founded by Jeffrey G. Spragens. North American Vaccine was acquired by Baxter International, Inc. on June 27, 2000 for $250.67 million. | 1 years |
| Pierre des Marais | M | - |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | 4 years |
| Gordon William Blankstein | M | 73 |
University of British Columbia
| 7 years |
| Jack H. L. Miller | M | - |
University of British Columbia
| 6 years |
| Pierre Labbé | M | 58 |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | 9 years |
| Lawrence Hineline | M | 67 |
North American Vaccine, Inc.
North American Vaccine, Inc. Pharmaceuticals: OtherHealth Technology North American Vaccine, Inc. develops and sells vaccines for the prevention of infectious diseases. The company is based in Columbia, MD. The company was founded by Jeffrey G. Spragens. North American Vaccine was acquired by Baxter International, Inc. on June 27, 2000 for $250.67 million. | 11 years |
| Jonathan Goodman | M | 56 |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | - |
| John Gandolfo | M | 63 | 6 years | |
| Jean M. Bellin | M | 74 | 10 years | |
| Gordon Ellis | M | 77 |
University of British Columbia
| 6 years |
| Farshad Guirakhoo | M | 70 | 5 years | |
| Ronald Tysoe | M | 71 |
University of British Columbia
| 5 years |
| James Hall | M | 79 | 11 years | |
| Pierre Johnson | M | 77 |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | - |
| P. Reifel | M | 72 |
University of British Columbia
| 6 years |
| Sharon Mates | M | 71 |
North American Vaccine, Inc.
North American Vaccine, Inc. Pharmaceuticals: OtherHealth Technology North American Vaccine, Inc. develops and sells vaccines for the prevention of infectious diseases. The company is based in Columbia, MD. The company was founded by Jeffrey G. Spragens. North American Vaccine was acquired by Baxter International, Inc. on June 27, 2000 for $250.67 million. | 9 years |
| Wade Dawe | M | 53 |
Rhino Resources, Inc. (Canada)
Immunovaccine Technologies, Inc.
| 4 years |
| Thomas Beattie | M | - |
University of British Columbia
| 5 years |
| Thomas P. Monath | M | 83 |
Acambis Plc
Acambis Plc BiotechnologyHealth Technology Acambis Plc develops biopharmaceutical products and vaccines. It offers ACAM2000, a smallpox vaccine for emergency-use stockpiling; and ChimeriVax-JE, a single-dose Japanese encephalitis vaccine for endemic markets and travelers. Its products in pipeline include ChimeriVax-JE, ChimeriVax-West Nile, and ChimeriVax-Dengue. The company was founded in 1992 and is headquartered in Cambridge, UK. | 14 years |
| George Alfio Pietrobon | M | 76 |
University of British Columbia
| 4 years |
| Richard P. Schutte | M | - |
University of British Columbia
| 4 years |
| Lam Sin Lai Tsui | M | 69 |
University of British Columbia
| 4 years |
| Robin Hutchison | M | 68 |
University of British Columbia
| 4 years |
| Terry Krepiakevich | M | 71 |
University of British Columbia
| 4 years |
| Brian L. Hauff | M | 72 |
University of British Columbia
| 3 years |
| Tom Richards | M | - |
University of British Columbia
| 3 years |
| Mark Ralston | M | 71 |
University of British Columbia
| 4 years |
| Uwe Schmidt | M | - |
University of British Columbia
| 4 years |
| David L. Adderley | M | 68 |
University of British Columbia
| 4 years |
| Bob Bebluk | M | - |
University of British Columbia
| 6 years |
| Zulkifli bin Mohammad Ali | M | 73 |
University of British Columbia
| 1 years |
| David Christie | M | 77 |
University of British Columbia
| 4 years |
| Brian Jones | M | - |
University of British Columbia
| 2 years |
| Howie Young | M | - |
University of British Columbia
| 4 years |
| Chris White | M | - |
University of British Columbia
| 4 years |
| Dale A. Sketchley | M | - |
University of British Columbia
| 4 years |
| Ross A. Mitchell | M | 74 |
University of British Columbia
| 4 years |
| Christopher Dyakowski | M | 72 |
University of British Columbia
| 4 years |
| Ken Ralfs | M | 76 |
University of British Columbia
| 4 years |
| Ross Beaty | M | 72 |
University of British Columbia
| 4 years |
| Yvan Joseph Bourdeau | M | - |
University of British Columbia
| 2 years |
| Arthur James Mcfaull | M | - |
University of British Columbia
| 4 years |
| Ian D. Power | M | - |
University of British Columbia
| 4 years |
| Richard Alfred Grafton | M | 70 |
University of British Columbia
| 4 years |
| Rajinder Chowdhry | M | 71 |
University of British Columbia
| 4 years |
| Robert George Lewis | M | - |
University of British Columbia
| 3 years |
| Andrew William Gourlay | M | - |
University of British Columbia
| 4 years |
| Frederic G. Hewett | M | - |
University of British Columbia
| 4 years |
| William R. LeClair | M | 71 |
University of British Columbia
| 4 years |
| James Albert Turner | M | 75 |
University of British Columbia
| 4 years |
| Ronald Ewing | M | - |
University of British Columbia
| 4 years |
| George Sookochoff | M | 72 |
University of British Columbia
| 4 years |
| Wan H. Jung | M | 67 |
University of British Columbia
| 4 years |
| William Pearson | M | - |
University of British Columbia
| 4 years |
| Neville Desmond Smith | M | 71 |
University of British Columbia
| 4 years |
| Bryan T. Nethery | M | - |
University of British Columbia
| 4 years |
| John Blanchflower | M | - |
University of British Columbia
| 4 years |
| Ronald J. Zokol | M | 74 |
University of British Columbia
| 4 years |
| Dickson Hall | M | 72 |
University of British Columbia
| 4 years |
| Andre J. Audet | M | - |
University of British Columbia
| 4 years |
| David Lyall | M | 68 |
University of British Columbia
| 4 years |
| Robert Waters | M | 73 |
University of British Columbia
| 4 years |
| Lee Herbert | M | 71 |
University of British Columbia
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Canada | 77 | 77.00% |
| United States | 20 | 20.00% |
| United Kingdom | 3 | 3.00% |
| Vietnam | 0 | -.--% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Randal Chase
- Personal Network
